Palladon (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride, the active ingredient in Palladon, is an opioid analgesic presented as a strength/form for oral use. It is prescribed for management of moderate to severe pain in adult patients when other analgesics are insufficient. GNH USA supplies Palladon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palladon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphone hydrochloride is an opioid that acts on the central nervous system to relieve pain. It is indicated for: - Acute postoperative pain: provides rapid relief of severe pain following surgery. - Cancer‑related pain: helps control persistent pain associated with malignant disease. - Severe chronic non‑cancer pain: used when other opioids or analgesics are ineffective.

Adverse reactions may range from mild to life‑threatening and should be monitored during therapy.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Constipation: reduced bowel motility. - Drowsiness or sedation: increased sleepiness. - Dizziness: light‑headed feeling. - Dry mouth: reduced salivation. - Pruritus: mild itching.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Acute withdrawal syndrome: signs of opioid dependence. - Anaphylaxis: severe allergic reaction. - Seizures: rare neurologic events. - Cardiac arrhythmias: abnormal heart rhythms.

Before initiating therapy, clinicians should evaluate patient history and potential risk factors. - Assess pain severity and prior opioid use: ensure appropriate indication. - Screen for respiratory disorders: avoid in patients with compromised breathing. - Monitor for signs of dependence or abuse: use caution in patients with substance‑use history. - Adjust dose in renal or hepatic impairment: consider reduced clearance. - Avoid concomitant CNS depressants: increased sedation risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Hydromorphone may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression. - Barbiturates: additive CNS depression may be life‑threatening. - Muscle relaxants: increased risk of sedation and respiratory compromise.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may enhance serotonergic effects. - Antihistamines: can increase drowsiness. - Anticonvulsants: may alter opioid metabolism. - CYP3A4 inhibitors (e.g., ketoconazole): raise hydromorphone plasma levels.